Protocol Ledger

NCT03419234 · Phase II · ACTIVE NOT RECRUITING

Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

Interventional Phase II clinical trial protocol NCT03419234 sponsored by ECOG-ACRIN Cancer Research Group in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-04-26 Enrollment: 223 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03419234
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)223 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03419234
Protocol FieldVerified Registry Value
NCT IdentifierNCT03419234
Consolidated Lead SponsorECOG-ACRIN Cancer Research Group
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment223 participants (ACTUAL)
Registered Start Date2018-04-26
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03419234
Hospital Research SiteLocationSite Profile
Fairbanks Memorial HospitalFairbanks, AKOpen Hospital Dossier ->
Kingman Regional Medical CenterKingman, AZOpen Hospital Dossier ->
Mercy Hospital Fort SmithFort Smith, AROpen Hospital Dossier ->
CHI Saint Vincent Cancer Center Hot SpringsHot Springs, AROpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI